IRLAB Therapeutics has raised SEK 138.6 million in a directed share issue to top tier investors in the US and Sweden
NOT FOR DISTRIBUTION OR PUBLIC RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH MEASURES WOULD BE IN VIOLATION OF APPLICABLE REGULATIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN IRLAB THERAPEUTICS IN ANY JURISDICTION. The Board of Directors of IRLAB Therapeutics AB (publ) has resolved, on the basis of the authorisation granted by the Annual General Meeting on 16 May 2018, to carry out a directed share issue corresponding to SEK